



05-26-04

1624 jw

EXPRESS MAIL CERTIFICATE

"Express Mail" mailing label number : EL 984 914 588 US

Date of Deposit : May 25, 2004

Type of Documents : Supplemental Information Disclosure Statement;
Form 1449 (1 page);
Cited References / two (2); and
Return Postcard

Serial No. : 09/864,905

Filing Date : May 24, 2001

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and are addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Heather Norman

(signature)



EL 984 914 588 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Miller, <i>et al.</i>)	Examiner: Hong Liu
)	
Serial No: 09/864,905)	Art Unit: 1624
)	
Filed: May 24, 2001)	
)	Docket No: T103 1421.1
For: Pharmaceutical Compositions and)	
Methods for Use)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants hereby voluntarily disclose the additional references listed on the attached Form PTO-1449 to the Commissioner for Patents. Copies of the two (2) references listed on Applicants' supplemental form PTO-1449 are enclosed herewith. Each item of information submitted with this Supplemental Information Disclosure Statement is being submitted before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114. Accordingly, no fees are believed due. However, should any fees be due in connection with this submission, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 09-0528.

Published international patent application, WO 96/30372 A1, is a Japanese language document with no apparent English equivalent readily available. According to the English abstract included in the published application, the reference appears to discuss diazabicyclo[3.3.1]nonane derivatives; intermediates thereof; and a nicotinic cholinergic agent containing the diazabicyclo[3.3.1]nonane derivatives. The compounds were alleged to have a nicotinic cholinergic effect and a dopamine-releasing effect, and alleged to be usable as a remedy

for dementia such as Alzheimer's disease, a drug for relieving memory disorders, a remedy for central nerve degeneration diseases, and a drug for relieving cerebral function disorders.


Applicants further reserve the right to establish the patentability of the claimed invention over any of the listed information should they be applied as references, and/or to prove that some of the cited information may not be prior art, and/or to prove that some of the cited information may not be enabling for the teachings they purport to offer.

This statement should not be construed as a representation that a search has been made, or that the information cited herewith is material, or that there does not exist information more material to the examination of the present Application. The Examiner is specifically requested not to rely solely on the information submitted herein. On the contrary, the Examiner is requested to conduct an independent and thorough review of all available information, and to form independent opinions as to its significance.

It is respectfully requested that the Examiner initial and return copies of the enclosed PTO-1449 and to indicate in the official file wrapper of the above-identified patent application that each item of the cited information has been considered.

Date:

May 25, 2004



Carl B. Massey, Jr.
Attorney for Applicants
Registration No. 44,224

Docket: **T103 1421.1**

Womble Carlyle Sandridge & Rice, PLLC
Post Office Box 7037
Atlanta, Georgia 30357-0037
Telephone (336) 721-3681
Facsimile(336) 726-8074

